Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep

Phase 4

Completed

• Conditions: Nasolabial Folds; Wrinkles
• Interventions: Device: Emervel Deep; Device: Emervel Classic

• Registration Number: NCT02672644
• Lead Sponsor: Galderma R&D

Brief Summary

Study is designed to characterize subject and treating investigator reported outcomes in the early post-treatment period, following bilateral correction of nasolabial folds using Emervel Classic and Emervel Deep.

1. to evaluate subject-reported return to social engagement, after the initial treatment (Baseline/Day 1 visit).

2. to evaluate change in Global Aesthetic Improvement Scale (GAIS) at day 30- subject/investigator reported

3. to evaluate subject satisfaction with treatment outcome at baseline, day 14 and day 30.

4. to evaluate change in Wrinkle Severity Rating Scale (WSRS) from baseline to post-treatment follow-up time points at day 14 and Day 30 - investigator reported

5. to evaluate all adverse events during the course of the study

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-01-26
• Study First Submitted QC: 2016-01-29
• Study First Posted: 2016-02-03
• Study Start: 2016-03
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Status Verified: 2016-07
• Last Update Submitted: 2022-07-28
• Last Update Posted: 2022-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Male or female subjects, 35 to 60 years of age
2. Bilateral NLFs: severe (WSRS = 4/4) or moderate (WSRS = 3/3), as assessed by the treating investigator
3. Subjects of childbearing potential who agree to use medically accepted methods of contraception during the study and for 30 days following study completion.

Childbearing potential is defined as not being surgically sterile (e.g., hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation) or those who are not post-menopausal (absence of menstruation for at least 1 year prior to Day 1).

• If not surgically sterile or post-menopausal, the subject agrees to use acceptable forms of contraception. Acceptable methods of contraception are defined as follows:

1. use of oral/systemic contraceptives for at least 3 months prior to the start of the study; or
2. use of an intrauterine device; or
3. use of double barrier (e.g., condom or diaphragm and spermicidal foam/gel, condom and diaphragm); or
4. use of contraceptive implants or injectables for at least 28 days prior to the start of the study; or
5. partner with vasectomy at least 3 months prior to study start; or
6. strict abstinence.

Females of child bearing potential must have negative urine pregnancy test (UPT) at Day 1 and Day 14 if touch-up is to be performed.

Key

Exclusion Criteria

1. Subject who presents with a severity of wrinkles or folds that require other treatments, e.g. laser treatment, chemical peeling, to achieve optimal correction
2. Previous facial surgery, including aesthetic facial surgical therapy, liposuction or tattoo, in the treatment area
3. Previous tissue augmenting therapy or contouring with permanent filler-type injectable product
4. Previous tissue augmenting therapy with non-permanent filler or fat-injection in the facial area to be treated, within twelve (12) months before treatment
5. Previous tissue revitalisation treatment with neurotoxin below the zygomatic arch, within six (6) months before treatment
6. Previous tissue revitalisation treatment with laser or light, mesotherapy, chemical peeling or dermabrasion below the zygomatic arch within six (6) months before treatment
7. Subject who presents with severe midface volume loss
8. Subject has a beard or facial hair that, in the investigator's opinion, would interfere with the study injections and/or study assessments
9. Woman who plans to become pregnant during the study
10. Woman who is pregnant or breast feeding
11. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel
12. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics
13. Known/previous allergy or hypersensitivity to gram-positive bacterial proteins
14. History of severe or multiple allergies manifested by anaphylaxis
15. History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation within two (2) weeks before treatment
16. Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids (inhaled corticoids are allowed) within three (3) months before study treatment
17. Any medical condition or treatment that, in the opinion of the treating investigator, would make the subject unsuitable for inclusion
18. Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees, or close relatives of employees at the Sponsor company
19. Participation in any clinical study within thirty (30) days before treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Emervel Deep	Emervel Deep	Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
Emervel Classic	Emervel Classic	Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.

Primary Outcome Measures

Name	Time	Method
Subject-reported time of return to social engagement after initial treatment	30 days	Time of return to social engagement (in hours)

Secondary Outcome Measures

Name	Time	Method
Change from baseline to post-treatment follow-up time points in subject reported GAIS	up to 30 days	Change from baseline to post-treatment follow-up time points in the subject reported GAIS (photographs) at day 30
Subject satisfaction with treatment outcome of the nasolabial folds	30 days	Subject satisfaction with treatment assessments at baseline, day 14, and day 30
Change from baseline to post-treatment follow-up time points in treating investigator reported WSRS	30 days	Change from baseline to post-treatment follow-up time points in the treating investigator reported WSRS at day 14 and day 30
Change from baseline to post-treatment follow-up time points in treating investigator reported GAIS	30 days	Change from baseline to post-treatment follow-up time points in the treating investigator reported GAIS (photographs) at day 30
Incidence rate of subjects with adverse events (AEs)	30 days
Incidence rate of subjects with injection-related adverse events	30 days	Injection-related adverse events recorded by the subject in study diary

Trial Locations

Locations (1)

Arthur Swift Research Inc.; 🇨🇦 Montreal, Quebec, Canada